In Re Monochloroacetic Acid (Mcaa) Antitrust Lit.

187 F. Supp. 2d 1381
CourtUnited States Judicial Panel on Multidistrict Litigation
DecidedFebruary 15, 2002
Docket1440
StatusPublished

This text of 187 F. Supp. 2d 1381 (In Re Monochloroacetic Acid (Mcaa) Antitrust Lit.) is published on Counsel Stack Legal Research, covering United States Judicial Panel on Multidistrict Litigation primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Monochloroacetic Acid (Mcaa) Antitrust Lit., 187 F. Supp. 2d 1381 (jpml 2002).

Opinion

187 F.Supp.2d 1381 (2002)

In re MONOCHLOROACETIC ACID (MCAA) ANTITRUST LITIGATION
Diamond Chemical Co., Inc.
v.
Akzo Nobel Chemicals BV, et al., D. District of Columbia, C.A. No. 1:01-2118.
Crompton Corp.
v.
Clariant Corp., et al., M.D. Louisiana, C.A. No. 3:01-84.

No. 1440.

Judicial Panel on Multidistrict Litigation.

February 15, 2002.

Before WM. TERRELL HODGES, Chairman, JOHN F. KEENAN, MOREY L. SEAR, BRUCE M. SELYA, JULIA SMITH GIBBONS, D. LOWELL JENSEN and J. FREDERICK MOTZ, Judges of the Panel.

*1382 ORDER DENYING TRANSFER

HODGES, Chairman.

This litigation consists of two actions pending, respectively, in the District of District of Columbia and the Middle District of Louisiana. Defendants ATOFINA Chemicals, Inc., and ATOFINA, S.A., move the Panel, pursuant to 28 U.S.C. § 1407, for an order centralizing this litigation in the Middle District of Louisiana. Responding defendants Akzo Nobel Chemicals BV and Akzo Nobel Functional Chemicals LLC oppose the motion, as do plaintiffs in both actions.

On the basis of the papers filed and hearing session held, the Panel finds that Section 1407 centralization would neither serve the convenience of the parties and witnesses nor further the just and efficient conduct of this litigation. Movants have failed to persuade us at this time that any common questions of fact and law in this docket are sufficiently complex, unresolved and/or numerous to justify Section 1407 transfer. We point out that alternatives to transfer exist that can minimize whatever possibilities there might be of duplicative discovery, inconsistent pretrial rulings, or both. See, e.g., In re Eli Lilly and Company (Cephalexin Monohydrate) Patent Litigation, 446 F.Supp. 242, 244 (Jud.Pan. Mult.Lit.1978). See also Manual for Complex Litigation, Third, § 31.14 (1995).

IT IS THEREFORE ORDERED that the motion, pursuant to 28 U.S.C. § 1407, for centralization of these two actions is DENIED.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Eli Lilly & Co.(cephalexin Monohydrate)
446 F. Supp. 242 (Judicial Panel on Multidistrict Litigation, 1978)
Diamond Chemical Co. v. Akzo Nobel Chemicals BV
187 F. Supp. 2d 1381 (Judicial Panel on Multidistrict Litigation, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
187 F. Supp. 2d 1381, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-monochloroacetic-acid-mcaa-antitrust-lit-jpml-2002.